{"id":4192,"date":"2026-04-15T18:13:58","date_gmt":"2026-04-15T12:43:58","guid":{"rendered":"https:\/\/higoodhealth.com\/india\/?p=4192"},"modified":"2026-05-16T12:21:24","modified_gmt":"2026-05-16T06:51:24","slug":"glp-1-drugs-explained","status":"publish","type":"post","link":"https:\/\/higoodhealth.com\/india\/glp-1-drugs-explained\/","title":{"rendered":"GLP-1 Drugs Explained: What They Are, How They Work, Benefits, Side Effects, and Safety in India (2026)"},"content":{"rendered":"\n<p><strong>The Drug That Changed Everything \u2014 And Why India Cannot Afford to Ignore It<\/strong><\/p>\n\n\n\n<p>Imagine a once-weekly injection that helps your body release insulin only when blood sugar is high, reduces constant food cravings, and \u2014 in large clinical trials \u2014 lowers the risk of heart attacks by 20% in people who are overweight. This is the proven science behind GLP-1 receptor agonist drugs, now more accessible in India than ever as of March 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A DISCOVERY OVER A CENTURY IN THE MAKING<\/h2>\n\n\n\n<p>The journey of GLP-1 medicines stretches back to 1906, when scientists in Liverpool first observed that extracts from the intestine could lower blood sugar. Although attention shifted after insulin was discovered, but the mystery of the gut\u2019s role in glucose regulation refused to die. <br><br>By the 1960s, researchers had demonstrated the incretin effect \u2014 the phenomenon where glucose taken orally triggers much higher insulin release than glucose given intravenously.The game-changing moment arrived in 1986\u201387, when Joel Habener and Svetlana Mojsov at Massachusetts General Hospital identified GLP-1, a truncated fragment of a glucagon-related protein with powerful insulin-stimulating properties.<br><br> In a landmark 1987 study, Mojsov synthesized GLP-1 and showed, using a perfused rat pancreas model, even tiny doses caused insulin levels to rise in lockstep.This foundational discovery \u2014 later recognized with the 2024 Lasker\u2013DeBakey Clinical Medical Research Award for Habener, Mojsov, and Lotte Bjerre Knudsen \u2014 laid the foundation for an entirely new class of medicines.<\/p>\n\n\n\n<p>Gut releases natural GLP-1 that is destroyed in the bloodstream within about two minutes by the enzyme DPP-4 that is a widely distributed integral membrane protein that is expressed in the intestine, kidney, vascular endothelium, liver pancreas, glandular epithelial cells, and immune system cells. <br><br>Hence, DPP-4 inhibitors are a successful class of anti-hyperglycaemic agents used to treat type 2 diabetes (T2DM) via protecting GLP-1. Dr. Daniel Drucker of the University of Toronto has noted: \u201cIn the field of diabetes research, the GLP-1 system may be the most important discovery since insulin.\u201d<\/p>\n\n\n\n<div class=\"wp-block-uagb-image uagb-block-a420fbda wp-block-uagb-image--layout-default wp-block-uagb-image--effect-static wp-block-uagb-image--align-none\"><figure class=\"wp-block-uagb-image__figure\"><img decoding=\"async\" srcset=\"https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-1-1024x572.webp ,https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-1-scaled.webp 780w, https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-1-scaled.webp 360w\" sizes=\"auto, (max-width: 480px) 150px\" src=\"https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-1-1024x572.webp\" alt=\"GLP-1 discovery timeline and mechanism \u2013 diabetes treatment infographic\" class=\"uag-image-4189\" width=\"1024\" height=\"572\" title=\"Part 1 - GLP1 India-1\" loading=\"lazy\" role=\"img\"\/><\/figure><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">WHY GLP-1 NEEDED REINVENTION<\/h2>\n\n\n\n<p>Natural GLP-1 is far too short-lived for medicine. To overcome this limitation, scientists searched nature for a more stable alternative. The solution came from an unlikely source: the saliva of the Gila monster lizard. A peptide called exendin-4 mimicked GLP-1 but lasted much longer. <br><br>This led to the first approved GLP-1 receptor agonist, exenatide (Byetta), in 2005 that bind to same receptor but work far longer. Subsequent engineering by Novo Nordisk\u2019s Lotte Knudsen produced liraglutide and then semaglutide \u2014 a once-weekly injection that binds to albumin in the blood for sustained action. Other agonists such as dulaglutide and tirzepatide was developed by Eli Lilly.<\/p>\n\n\n\n<p>Why does this matter for India? India is home to over 100 million people with diabetes and approximately 250 million classified as obese or overweight. What makes the situation uniquely dangerous is the \u201cThin-Fat Indian\u201d paradox: South Asians tend to accumulate more visceral (belly) fat, liver fat, and less lean muscle mass at lower body weights than Western populations. <br><br>A person with a BMI of 24 in India can carry the same metabolic risk as someone with a BMI of 30 in Europe. The WHO has recommended lower BMI cut-offs for overweight (\u226523 kg\/m\u00b2) and obesity (\u226525 kg\/m\u00b2) in Asian populations for precisely this reason.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The 2026 Turning Point: Affordable Access<\/h3>\n\n\n\n<p>Following the expiry of semaglutide\u2019s patent in India (March 20\u201321, 2026), the market changed dramatically.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>40+ Indian pharma companies launched generics<\/li>\n\n\n\n<li>Prices dropped by ~80%<\/li>\n<\/ul>\n\n\n\n<p>Key players include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sun Pharma<\/li>\n\n\n\n<li>Dr. Reddy&#8217;s Laboratories<\/li>\n\n\n\n<li>Cipla<\/li>\n\n\n\n<li>Lupin<\/li>\n\n\n\n<li>Zydus Lifesciences<\/li>\n<\/ul>\n\n\n\n<p>Pricing shift:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Earlier: \u20b910,000\u201311,000\/month (branded)<\/li>\n\n\n\n<li>Now: ~\u20b93,000\u20135,000\/month (generics)<\/li>\n<\/ul>\n\n\n\n<p>In response, Novo Nordisk introduced more affordable branded alternatives like <strong>Extensior<\/strong> and <strong>Poviztra<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">&nbsp;What Is a GLP-1 Drug?<\/h3>\n\n\n\n<p>GLP-1 (Glucagon-Like Peptide-1) is a natural gut hormone released by intestinal L-cells after eating. It acts as the body&#8217;s built-in regulator of appetite and blood sugar. GLP-1 works by: stimulating insulin only when blood sugar is high, reducing liver glucose output, slowing stomach emptying to prolong fullness, suppressing hunger via the brain, and inhibiting glucagon to maintain stable glucose levels.<\/p>\n\n\n\n<p><strong>And How Do GLP-1 Drugs Work? The Mechanism Explained Simply<\/strong><\/p>\n\n\n\n<p>Imagine your digestive system as a smart factory. When raw material (food) arrives, the factory needs to process it efficiently. GLP-1 drugs work like an upgraded factory supervisor who coordinates multiple departments at once:\u2019<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pancreas (Smart Insulin Release): Stimulates insulin only when blood sugar is high \u2192 stops when sugar normalizes \u2192 low risk of hypoglycemia (unlike older drugs)<\/li>\n\n\n\n<li>Brain (Appetite Control): Acts on hypothalamus &amp; brainstem \u2192 reduces food cravings \u2192 food loses emotional grip<\/li>\n\n\n\n<li>Stomach (Slow Emptying): Delays gastric emptying \u2192 smaller meals keep you full longer<\/li>\n\n\n\n<li>Liver (Reduced Sugar Output): Suppresses glucagon \u2192 lowers excessive glucose release from liver \u2192 improves fasting blood sugar (especially beneficial for insulin-resistant individuals, common in Indian populations)<\/li>\n\n\n\n<li>Beyond Blood Sugar (Multi-Organ Effects): GLP-1 receptors found in heart, blood vessels, kidneys, brain \u2192 being studied for heart failure, kidney disease, fatty liver (NAFLD\/NASH), Parkinson&#8217;s, and Alzheimer&#8217;s<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">GLP-1 Drugs Available in India: Names, Forms, and Costs (2026)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Generic Name<\/strong><\/td><td><strong>Brand Names<\/strong><\/td><td><strong>Type<\/strong><\/td><td><strong>Approved For<\/strong><\/td><td><strong>Approx. Cost\/Month<\/strong><\/td><td><strong>Key Feature<\/strong><\/td><\/tr><tr><td>Semaglutide<\/td><td>Ozempic, Wegovy, Rybelsus<\/td><td>Weekly injection \/ Daily oral<\/td><td>T2D, Obesity<\/td><td>\u20b93,400\u2013\u20b916,400<\/td><td>Most studied; generics dominant<\/td><\/tr><tr><td>Tirzepatide<\/td><td>Mounjaro<\/td><td>Weekly injection<\/td><td>T2D, Obesity<\/td><td>\u20b914,000\u2013\u20b927,500<\/td><td>Dual GLP-1 + GIP; highest weight loss<\/td><\/tr><tr><td>Liraglutide<\/td><td>Victoza, Saxenda, Lirafit<\/td><td>Daily injection<\/td><td>T2D, Obesity<\/td><td>\u20b94,000\u2013\u20b912,000<\/td><td>Older, well-established safety<\/td><\/tr><tr><td>Dulaglutide<\/td><td>Trulicity<\/td><td>Weekly injection<\/td><td>T2D<\/td><td>\u20b93,500\u2013\u20b98,000<\/td><td>Convenient pen device<\/td><\/tr><tr><td>Exenatide<\/td><td>Byetta, Bydureon<\/td><td>Twice-daily or weekly<\/td><td>T2D<\/td><td>\u20b93,000\u2013\u20b96,000<\/td><td>First GLP-1 (2005)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Important note:<\/strong> Oral semaglutide (Rybelsus) is currently approved in India only for Type 2 diabetes, not for weight loss. Always verify current approvals with your prescribing physician.<\/p>\n\n\n\n<p>All four (Semaglutide, Liraglutide, Dulaglutide, and Tirzepatide) are approved by CDSCO (Central Drugs Standard Control Organization) in India for managing diabetes, with Semaglutide and Liraglutide being common choices for weight management.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.japi.org\/article\/japi-74-3-103\" target=\"_blank\" rel=\"noopener\">https:\/\/www.japi.org\/article\/japi-74-3-103<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Why GLP-1 Drugs Became Famous: Is This a Revolution in Medicine?<\/h3>\n\n\n\n<p>The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reduction\u2014approaching bariatric surgery outcomes.<br><br> The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss. <br><br>In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function. Additional benefits include better HbA1c (1.0\u20131.8% reduction), modest blood pressure improvement, and favorable lipid changes. <br><br>Emerging research covers fatty liver, kidney disease, sleep apnoea, PCOS, and neurodegeneration. Dr. Rajiv Kovil notes nearly 50% of his patients could benefit, but only 5% used them due to cost\u2014generics are now changing this.<\/p>\n\n\n\n<p>This meta-analysis of 16 studies (5,997 patients) found that Semaglutide significantly reduced HbA1c compared to Liraglutide (0.56; p &lt; 0.001) and Dulaglutide (3.72; p = 0.05), and also lowered FBS more than Dulaglutide (2.66; p = 0.03). No significant differences were observed in weight or BMI changes. Tirzepatide showed superior HbA1c reduction over Semaglutide (\u22120.45; p = 0.04), with no differences in weight or FBS.<\/p>\n\n\n\n<div class=\"wp-block-uagb-image uagb-block-928daed0 wp-block-uagb-image--layout-default wp-block-uagb-image--effect-static wp-block-uagb-image--align-none\"><figure class=\"wp-block-uagb-image__figure\"><img decoding=\"async\" sizes=\"auto, (max-width: 480px) 150px\" src=\"https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-2-scaled.webp\" alt=\"\" width=\"2560\" height=\"1429\" title=\"\" loading=\"lazy\" role=\"img\"><\/figure><\/div>\n\n\n\n<p><a href=\"https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2025.1438318\/full\" target=\"_blank\" rel=\"noopener\">https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2025.1438318\/full<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Key Benefits of GLP-1 Drugs <\/h3>\n\n\n\n<p>Clinically significant weight loss: 10\u201321% of body weight in trials \u2022 Better blood sugar control with low risk of hypoglycaemia \u2022 Proven cardiovascular protection (20% MACE reduction) \u2022 Natural appetite regulation and reduced emotional eating \u2022 Convenient once-weekly dosing that improves adherence \u2022 Multi-organ benefits under active study<\/p>\n\n\n\n<p><strong>Side Effects: What You Should Know<\/strong><\/p>\n\n\n\n<p>Most side effects are manageable and improve as your body adjusts over the first 2\u20134 weeks.<\/p>\n\n\n\n<p><strong>Common Side Effects (experienced by 10\u201340% of users)<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Side Effect<\/strong><\/td><td><strong>Why It Happens<\/strong><\/td><td><strong>What Helps<\/strong><\/td><\/tr><tr><td>Nausea<\/td><td>Slowed stomach emptying; brain activation<\/td><td>Eat smaller meals; avoid fried\/greasy food; hydrate<\/td><\/tr><tr><td>Vomiting<\/td><td>Related to nausea, more common during dose escalation<\/td><td>Slow dose titration under doctor\u2019s guidance<\/td><\/tr><tr><td>Diarrhoea<\/td><td>Altered gut motility<\/td><td>Stay hydrated with nimbu pani or ORS; avoid dairy temporarily<\/td><\/tr><tr><td>Constipation<\/td><td>Slowed gastric and intestinal motility<\/td><td>Increase fibre (isabgol, vegetables, whole grains); drink more water<\/td><\/tr><tr><td>Bloating \/ Gas<\/td><td>Slower digestion<\/td><td>Eat slowly; avoid carbonated drinks; consider ajwain water<\/td><\/tr><tr><td>Reduced appetite<\/td><td>Intended mechanism<\/td><td>Ensure adequate protein and nutrient intake<\/td><\/tr><tr><td>Injection site reactions<\/td><td>Local immune response<\/td><td>Rotate injection sites; use room-temperature pen<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Serious but Rare Side Effects<\/strong> (require immediate medical attention):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li> Pancreatitis: severe abdominal pain radiating to the back <\/li>\n\n\n\n<li>Gallbladder problems: increased gallstone risk from rapid weight loss<\/li>\n\n\n\n<li>Thyroid concerns: contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2<\/li>\n\n\n\n<li>Severe hypoglycaemia: rare alone but higher risk with insulin or sulphonylureas<\/li>\n<\/ul>\n\n\n\n<p><strong>Misuse, Myths, and Misinformation: What India Needs to Know<\/strong><\/p>\n\n\n\n<p>With social media flooded with dramatic before-and-after transformations, GLP-1 drugs are rapidly becoming <strong>misunderstood\u2014and misused\u2014across India<\/strong>.<\/p>\n\n\n\n<p>These are not lifestyle products. They are <strong>powerful metabolic medications<\/strong> that require responsible use.<\/p>\n\n\n\n<p><strong>Myth 1<\/strong>: \u201cGLP-1 drugs are a cosmetic shortcut to look slim.\u201d<\/p>\n\n\n\n<p><strong>Reality<\/strong>: These are serious prescription medications approved for Type 2 diabetes and clinical obesity (BMI \u226530, or \u226527 with metabolic complications). Not for minor cosmetic loss.<\/p>\n\n\n\n<p><strong>Myth 2<\/strong>: \u201cIf it is available at the pharmacy, I can buy and use it myself.\u201d<\/p>\n\n\n\n<p><strong>Reality<\/strong>: The Indian government issued a directive on 24 March 2026 flagging unauthorised sales. Buying without prescription risks incorrect dosing, missed conditions, and counterfeit products.<\/p>\n\n\n\n<p><strong>Myth 3<\/strong>: \u201cI can take GLP-1 drugs and skip exercise and a healthy diet.\u201d<\/p>\n\n\n\n<p><strong>&nbsp;Reality<\/strong>: They supplement \u2014 never replace \u2014 lifestyle. Without adequate protein (1.0\u20131.2 g\/kg) and strength training, rapid weight loss can cause significant muscle loss (sarcopenia), especially dangerous for Indians with lower baseline lean muscle.<\/p>\n\n\n\n<p><strong>Myth 4<\/strong>: \u201cAnyone with a lower BMI can use it to slim down.\u201d<\/p>\n\n\n\n<p><strong>Reality:<\/strong> Medically unjustified and potentially harmful.<\/p>\n\n\n\n<p><strong>Myth 5<\/strong>: \u201cOnline influencers and advertisements know best.\u201d<\/p>\n\n\n\n<p><strong>Reality:<\/strong> Only qualified endocrinologists or diabetologists should guide decisions.<\/p>\n\n\n\n<p><strong>Essential Precautions<\/strong> \u2022 Use ONLY under medical supervision with comprehensive baseline tests (HbA1c, fasting insulin, lipids, kidney\/liver\/thyroid).<\/p>\n\n\n\n<p>\u2022 Avoid during pregnancy and lactation; use effective contraception and discontinue at least 2 months before planning pregnancy.<\/p>\n\n\n\n<p>\u2022 Discuss gallbladder and GI risks if you have history of gallstones, pancreatitis, or IBD.<\/p>\n\n\n\n<p>\u2022 Contraindicated in MTC or MEN 2 family history.<\/p>\n\n\n\n<p>\u2022 Watch for muscle loss: prioritise resistance training and protein-rich Indian foods (paneer, dal, tofu, soy, sprouts, nuts, seeds).<\/p>\n\n\n\n<p>&nbsp;\u2022 Maintain cold chain storage (2\u20138\u00b0C).<\/p>\n\n\n\n<p>\u2022 Inform your doctor about all medications for necessary dose adjustments.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-3-1024x572.webp\" alt=\"GLP-1 drugs myths vs safety guide \u2013 medical infographic\" class=\"wp-image-4191\" title=\"\" srcset=\"https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-3-1024x572.webp 1024w, https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-3-300x167.webp 300w, https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-3-768x429.webp 768w, https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-3-1536x857.webp 1536w, https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/Part-1-GLP1-India-3-2048x1143.webp 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Who Should Talk to a Doctor Before Starting?<\/strong> <\/p>\n\n\n\n<p>Everyone should consult before starting. Priority for people with uncontrolled Type 2 diabetes, clinical obesity, abdominal obesity (waist \u226590 cm men, \u226580 cm women), PCOS, obstructive sleep apnoea, hypertension, dyslipidaemia, strong family history of metabolic disease, insulin users, or fatty liver. Many metabolic issues remain silent; waist-to-height ratio &gt;0.5 signals risk even if BMI looks normal \u2014 the Thin-Fat Indian reality.<\/p>\n\n\n\n<p><strong>Latest Scientific Studies on GLP-1 Drugs (2023\u20132026)<\/strong><\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>SELECT Trial (NEJM, 2023): 17,604 patients; 20% reduction in major cardiovascular events and 19% lower all-cause death in obesity without diabetes.<\/li>\n\n\n\n<li>STEP-HFpEF Trial (NEJM, 2023): 13.3% weight loss plus major improvements in HFpEF symptoms and function.<\/li>\n\n\n\n<li>SURMOUNT-1 Trial (NEJM, 2022): Tirzepatide up to 20.9% weight loss.<\/li>\n\n\n\n<li>Semaglutide vs. Tirzepatide (JAMA Internal Medicine, 2024): Tirzepatide showed greater weight loss; choice depends on individual profile, goals, and budget.<\/li>\n\n\n\n<li>India-Specific: The Indian Practitioner (March 2026) highlights need for local data and warns against unregulated \u201cGLP-1 alternative\u201d supplements.<\/li>\n\n\n\n<li>Cagrisema ( cagrilintide + semaglutide;Norvo \/nordisk) is currently in phase&nbsp;&nbsp; III trials.<a href=\"https:\/\/pharmaceutical-journal.com\/article\/feature\/beyond-glp-1-the-next-wave-of-weight-loss-medication-innovation#:~:text=GLP%2D1s%20Wegovy%20(semaglutide;,2027\" target=\"_blank\" rel=\"noopener\"> <\/a><a href=\"https:\/\/pharmaceutical-journal.com\/article\/feature\/beyond-glp-1-the-next-wave-of-weight-loss-medication-innovation#:~:text=GLP%2D1s%20Wegovy%20(semaglutide;,2027\" target=\"_blank\" rel=\"noopener\">https:\/\/pharmaceutical-journal.com\/article\/feature\/beyond-glp-1-the-next-wave-of-weight-loss-medication-innovation#:~:text=GLP%2D1s%20Wegovy%20(semaglutide;,2027<\/a><\/li>\n<\/ol>\n\n\n\n<p><strong>India-Specific Reality: What You Need to Remember<\/strong> <\/p>\n\n\n\n<p>India is not a smaller version of the West. BMI alone is misleading; use waist circumference and waist-to-height ratio. Protein is non-negotiable (aim 1.0\u20131.2 g\/kg from paneer, dal, soy, sprouts, nuts). Resistance training 3\u20134 times weekly is critical to prevent sarcopenia. Buy only from licensed pharmacies to avoid counterfeits. The right patient, right dose, and right monitoring are essential.<\/p>\n\n\n\n<p><strong>Supporting Your Health Naturally: Nutrition and Lifestyle Tips<\/strong><\/p>\n\n\n\n<p> High-fibre foods (oats, millets, vegetables, legumes) feed gut bacteria that stimulate natural GLP-1. Fermented foods (idli, curd), healthy fats (nuts, seeds, mustard oil), protein staples, and spices (turmeric, cinnamon, methi) support metabolic health. Lifestyle: 30\u201345 min post-meal walk, resistance\/yoga 3\u20134\u00d7\/week, 7\u20138 hours sleep, stress management through pranayama, and 2.5\u20133 L water daily.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Frequently Asked Questions (FAQs)<\/h4>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list \">\n<div id=\"faq-question-1776255724505\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Is Ozempic available in India?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Yes. Novo Nordisk launched Ozempic (semaglutide injection) in India in December 2025. Since the patent expired in March 2026, multiple generic versions from Sun Pharma, Dr. Reddy\u2019s, Natco, Cipla, and others are also now available at significantly lower prices.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255738369\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">What is the cost of GLP-1 drugs in India?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>A: Prices range widely. Branded semaglutide (Ozempic\/Wegovy) costs approximately \u20b98,800\u2013\u20b916,400\/month. Generic semaglutide is now available from approximately \u20b93,400\/month. Tirzepatide (Mounjaro) costs \u20b914,000\u2013\u20b927,500\/month depending on dose. Older options like liraglutide (Victoza\/Lirafit) may cost \u20b94,000\u2013\u20b912,000\/month.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255776324\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can I use GLP-1 drugs just for weight loss without diabetes?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>A: Wegovy (semaglutide at higher dose) and Mounjaro (tirzepatide) have received approval for obesity management in adults with BMI \u226530 (or \u226527 with metabolic complications). However, they must be prescribed by a qualified doctor after a thorough medical evaluation. They are not for cosmetic weight loss.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255797281\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \"> Are GLP-1 drugs safe for vegetarians?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>A: Yes. GLP-1 drugs are synthetic peptides manufactured in laboratories. They do not contain any animal-derived ingredients in their active formulation. However, always check with your pharmacist regarding excipients in specific brands if you have dietary concerns.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255825828\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">How long do I need to take GLP-1 drugs?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>A: Most clinical trials show that weight regain occurs after stopping the medication. Current evidence suggests these are long-term treatments, similar to blood pressure or cholesterol medications. However, the duration should be decided by your doctor based on your individual response and health goals.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255875701\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can I buy GLP-1 drugs without a prescription in India?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p> These are prescription-only medications. Buying without a prescription is both illegal and dangerous. The Indian government has specifically warned against unauthorised sales of GLP-1 drugs.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255918100\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">What is the difference between Ozempic and Wegovy?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Both contain semaglutide. Ozempic is approved for Type 2 diabetes (doses up to 1 mg\/week). Wegovy is the same molecule at a higher dose (2.4 mg\/week) approved specifically for weight management.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255936974\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">What is the difference between semaglutide and tirzepatide?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p> A: Semaglutide (Ozempic\/Wegovy) targets only GLP-1 receptors. Tirzepatide (Mounjaro) is a dual agonist targeting both GLP-1 and GIP receptors, which tends to produce greater weight loss. However, tirzepatide is more expensive and still under patent.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255973145\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Will GLP-1 drugs replace bariatric surgery?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>A: Not entirely. Bariatric surgery remains the gold standard for severe obesity (BMI \u226540 or \u226535 with complications). GLP-1 drugs offer a less invasive option for moderate obesity and may reduce the number of patients who need surgery.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1776255988696\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Are there any natural alternatives to GLP-1 drugs?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>A: No supplement can replicate the effects of prescription GLP-1 drugs. However, a high-fibre, whole-food diet, regular exercise, adequate sleep, and stress management can naturally support your body\u2019s own GLP-1 production and improve metabolic health. Be very cautious about OTC products marketed as \u201cGLP-1 alternatives\u201d \u2014 most lack clinical evidence.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<h4 class=\"wp-block-heading\">Glossary of Key Terms<\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Term \/ Abbreviation<\/strong><\/td><td><strong>Definition<\/strong><\/td><\/tr><tr><td><strong>GLP-1<\/strong><\/td><td>Glucagon-Like Peptide-1 \u2014 a natural hormone released by the gut that regulates blood sugar and appetite.<\/td><\/tr><tr><td><strong>GIP<\/strong><\/td><td>Glucose-Dependent Insulinotropic Polypeptide \u2014 another incretin hormone; targeted by dual-agonist drugs like tirzepatide.<\/td><\/tr><tr><td><strong>GLP-1 Receptor Agonist (GLP-1 RA)<\/strong><\/td><td>A drug that mimics GLP-1 by binding to its receptors, producing sustained blood sugar and weight management effects.<\/td><\/tr><tr><td><strong>Incretin<\/strong><\/td><td>A class of gut hormones that stimulate insulin release in response to food intake.<\/td><\/tr><tr><td><strong>DPP-4<\/strong><\/td><td>Dipeptidyl Peptidase-4 \u2014 an enzyme that rapidly breaks down natural GLP-1 in the body.<\/td><\/tr><tr><td><strong>HbA1c<\/strong><\/td><td>Glycated haemoglobin \u2014 a blood test measuring average blood sugar over the past 2\u20133 months.<\/td><\/tr><tr><td><strong>BMI<\/strong><\/td><td>Body Mass Index \u2014 weight (kg) divided by height (m) squared. Indian cut-offs: overweight \u226523, obese \u226525.<\/td><\/tr><tr><td><strong>MACE<\/strong><\/td><td>Major Adverse Cardiovascular Events \u2014 a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke.<\/td><\/tr><tr><td><strong>Sarcopenia<\/strong><\/td><td>Loss of muscle mass and strength, a particular risk during rapid weight loss.<\/td><\/tr><tr><td><strong>NAFLD\/NASH<\/strong><\/td><td>Non-Alcoholic Fatty Liver Disease \/ Non-Alcoholic Steatohepatitis \u2014 fat accumulation and inflammation in the liver.<\/td><\/tr><tr><td><strong>HFpEF<\/strong><\/td><td>Heart Failure with Preserved Ejection Fraction \u2014 a type of heart failure where the heart pumps normally but stiffens.<\/td><\/tr><tr><td><strong>PCOS<\/strong><\/td><td>Polycystic Ovary Syndrome \u2014 a hormonal disorder linked to insulin resistance and weight gain.<\/td><\/tr><tr><td><strong>MTC<\/strong><\/td><td>Medullary Thyroid Carcinoma \u2014 a rare thyroid cancer; GLP-1 drugs are contraindicated if you have personal or family history.<\/td><\/tr><tr><td><strong>MEN 2<\/strong><\/td><td>Multiple Endocrine Neoplasia syndrome type 2 \u2014 a genetic condition involving thyroid and adrenal tumours.<\/td><\/tr><tr><td><strong>T2D<\/strong><\/td><td>Type 2 Diabetes Mellitus.<\/td><\/tr><tr><td><strong>CDSCO<\/strong><\/td><td>Central Drugs Standard Control Organization \u2014 India\u2019s national regulatory body for pharmaceuticals.<\/td><\/tr><tr><td><strong>ICMR<\/strong><\/td><td>Indian Council of Medical Research.<\/td><\/tr><tr><td><strong>FSSAI<\/strong><\/td><td>Food Safety and Standards Authority of India.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>All reference links valid and accessible on 10 April 2026<\/strong><\/h4>\n\n\n\n<p><a href=\"https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2019.00260\/full\" data-type=\"link\" data-id=\"https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2019.00260\/full\" target=\"_blank\" rel=\"noopener\"><strong>1. <\/strong>Holst JJ. From the Incretin Concept and the Discovery of GLP-1 to Today\u2019s Diabetes Therapy. Frontiers in Endocrinology, 2019.<\/a><\/p>\n\n\n\n<p><strong>2. <\/strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10786682\/\" data-type=\"link\" data-id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10786682\/\" target=\"_blank\" rel=\"noopener\">Drucker DJ. The GLP-1 Journey: From Discovery Science to Therapeutic Impact. Journal of Clinical Investigation, 2024.<\/a><\/p>\n\n\n\n<p><strong>3. <\/strong><a href=\"https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2019.00155\/full\" data-type=\"link\" data-id=\"https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2019.00155\/full\" target=\"_blank\" rel=\"noopener\">Lau J et al. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 2019.<\/a><\/p>\n\n\n\n<p><strong>4.<\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37952131\/\" data-type=\"link\" data-id=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37952131\/\" target=\"_blank\" rel=\"noopener\"><strong> <\/strong>Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT Trial). NEJM, 2023.<\/a><\/p>\n\n\n\n<p><strong>5. <\/strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11897845\/\" data-type=\"link\" data-id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11897845\/\" target=\"_blank\" rel=\"noopener\">Safety Profile of Semaglutide in the SELECT Study. Obesity (PMC), 2025.<\/a><\/p>\n\n\n\n<p><strong>6. <\/strong>J<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2206038\" data-type=\"link\" data-id=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\">astreboff AM et al. Tirzepatide for Treatment of Obesity (SURMOUNT-1). NEJM, 2022.<\/a><\/p>\n\n\n\n<p><strong>7.<\/strong><a href=\"https:\/\/theindianpractitioner.com\/glp1-ra-and-weight-loss-boom-in-india-trends-concerns-and-caution-dr-amit-bhargava-dr-varsha-narayanan\/\" data-type=\"link\" data-id=\"https:\/\/theindianpractitioner.com\/glp1-ra-and-weight-loss-boom-in-india-trends-concerns-and-caution-dr-amit-bhargava-dr-varsha-narayanan\/\" target=\"_blank\" rel=\"noopener\"><strong> <\/strong>Bhargava A, Narayanan V. GLP1-RA and Weight Loss Boom in India. The Indian Practitioner, 2026.<\/a><\/p>\n\n\n\n<p><strong>8. <\/strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4026332\/\" data-type=\"link\" data-id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4026332\/\" target=\"_blank\" rel=\"noopener\">Diabetes and Associated Complications in the South Asian Population. PMC.<\/a><\/p>\n\n\n\n<p><strong>9. <\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30115487\/\" data-type=\"link\" data-id=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30115487\/\" target=\"_blank\" rel=\"noopener\">Misra A et al. Body Fat, Metabolic Syndrome and Hyperglycemia in South Asians. PubMed, 2018.<\/a><\/p>\n\n\n\n<p><strong>10. <\/strong><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3738996\/\" data-type=\"link\" data-id=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3738996\/\" target=\"_blank\" rel=\"noopener\">Obesity and Dyslipidemia in South Asians. PMC, 2013.<\/a><\/p>\n\n\n\n<p><strong>11. <\/strong><a href=\"https:\/\/diabetesjournals.org\/care\/article\/47\/1\/7\/154008\/Diabetes-in-South-Asians-Uncovering-Novel-Risk\" data-type=\"link\" data-id=\"https:\/\/diabetesjournals.org\/care\/article\/47\/1\/7\/154008\/Diabetes-in-South-Asians-Uncovering-Novel-Risk\" target=\"_blank\" rel=\"noopener\">Kanaya AM. Diabetes in South Asians: Uncovering Novel Risk Factors. Diabetes Care, 2024.<\/a><\/p>\n\n\n\n<p><strong>12. <\/strong><a href=\"https:\/\/www.grandviewresearch.com\/industry-analysis\/india-glp-1-receptor-agonist-market-report\" data-type=\"link\" data-id=\"https:\/\/www.grandviewresearch.com\/industry-analysis\/india-glp-1-receptor-agonist-market-report\" target=\"_blank\" rel=\"noopener\">India GLP-1 Receptor Agonist Market Report 2030. Grand View Research.<\/a><\/p>\n\n\n\n<p><strong>13.<\/strong><a href=\"https:\/\/www.india-briefing.com\/news\/ozempic-generic-glp1-drug-manufacturing-race-in-india-43676.html\/\" data-type=\"link\" data-id=\"https:\/\/www.india-briefing.com\/news\/ozempic-generic-glp1-drug-manufacturing-race-in-india-43676.html\/\" target=\"_blank\" rel=\"noopener\"><strong> <\/strong>India\u2019s GLP-1 Market Set for Shake-up. India Briefing, March 2026.<\/a><\/p>\n\n\n\n<p><strong>14. <\/strong><a href=\"https:\/\/www.cnbc.com\/2026\/03\/23\/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html\" data-type=\"link\" data-id=\"https:\/\/www.cnbc.com\/2026\/03\/23\/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html\" target=\"_blank\" rel=\"noopener\">CNBC: India Is Launching Cheap Weight-Loss Drugs, March 2026.<\/a><\/p>\n\n\n\n<p><strong>15.<\/strong><a href=\"https:\/\/diabetesatlas.org\/\" data-type=\"link\" data-id=\"https:\/\/diabetesatlas.org\/\" target=\"_blank\" rel=\"noopener\"><strong> <\/strong>International Diabetes Federation. IDF Diabetes Atlas, 2024.<\/a><\/p>\n\n\n\n<p><strong>16. <\/strong><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(03)15268-3\/fulltext\" data-type=\"link\" data-id=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(03)15268-3\/fulltext\" target=\"_blank\" rel=\"noopener\">WHO Expert Consultation: Appropriate BMI for Asian Populations. Lancet, 2004.<\/a><\/p>\n\n\n\n<p>17. <a href=\"https:\/\/doi.org\/10.3389\/fendo.2019.00080\" data-type=\"link\" data-id=\"https:\/\/doi.org\/10.3389\/fendo.2019.00080\" target=\"_blank\" rel=\"noopener\">Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.<\/a>.<\/p>\n\n\n\n<p>18. <a href=\"https:\/\/doi.org\/10.3390\/molecules27134315\" data-type=\"link\" data-id=\"https:\/\/doi.org\/10.3390\/molecules27134315\" target=\"_blank\" rel=\"noopener\">Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Disclaimer<\/h4>\n\n\n\n<p><strong>Medical Disclaimer: <\/strong>This article is published for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this blog. The information provided here is based on publicly available research and data as of April 2026 and may not reflect the most current medical guidelines. HiGoodHealth.com and its contributors do not endorse, recommend, or promote any specific drug, brand, pharmaceutical company, or treatment. Individual responses to medications vary, and treatment decisions should always be made in consultation with a qualified medical professional who is aware of your complete medical history.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">About HiGoodHealth<\/h4>\n\n\n\n<p><strong><a href=\"http:\/\/higoodhealth.com\/\" data-type=\"link\" data-id=\"http:\/\/higoodhealth.com\/\">HiGoodHealth.com<\/a><\/strong> is a health and wellness platform dedicated to sharing clean, credible, evidence-based health information with communities across India and beyond. Our mission is simple: empower every person to make informed health decisions through content that is accurate, accessible, and free from misinformation. We strive to bust health myths, encourage healthy living, share best practices and assets from global research and diverse communities, and make complex medical topics understandable for everyone \u2014 from a first-time reader to a health-savvy professional.<\/p>\n\n\n\n<p><strong>We value your feedback! <\/strong>If you found this article helpful, share it with your family and friends. Have a health topic you would like us to cover? Write to us through our website or leave a comment. Together, we are building a healthier, more informed India.<\/p>\n\n\n\n<p>Explore our other popular articles on <em>antioxidants, grain nutrition, sweeteners, balance and fall prevention, oral health<\/em>, and more at <a href=\"http:\/\/higoodhealth.com\/\" data-type=\"link\" data-id=\"http:\/\/higoodhealth.com\/\"><strong>HiGoodHealth.com<\/strong>.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Drug That Changed Everything \u2014 And Why India Cannot Afford to Ignore It Imagine a once-weekly injection that helps your body release insulin only when blood sugar is high, reduces constant food cravings, and \u2014 in large clinical trials \u2014 lowers the risk of heart attacks by 20% in people who are overweight. This &#8230; <a title=\"GLP-1 Drugs Explained: What They Are, How They Work, Benefits, Side Effects, and Safety in India (2026)\" class=\"read-more\" href=\"https:\/\/higoodhealth.com\/india\/glp-1-drugs-explained\/\" aria-label=\"Read more about GLP-1 Drugs Explained: What They Are, How They Work, Benefits, Side Effects, and Safety in India (2026)\">Read more<\/a><\/p>\n","protected":false},"author":28,"featured_media":4198,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","footnotes":""},"categories":[41,8,3,31],"tags":[],"ppma_author":[74,67],"class_list":["post-4192","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthtech-latest-articles","category-holistic-health-lifestyle-integration","category-nutrition-well-being","category-popular-articles","author-diksha01","author-vasundhara"],"uagb_featured_image_src":{"full":["https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/glp.jpeg",1600,1600,false],"thumbnail":["https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/glp-150x150.jpeg",150,150,true],"medium":["https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/glp-300x300.jpeg",300,300,true],"medium_large":["https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/glp-768x768.jpeg",768,768,true],"large":["https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/glp-1024x1024.jpeg",1024,1024,true],"1536x1536":["https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/glp-1536x1536.jpeg",1536,1536,true],"2048x2048":["https:\/\/higoodhealth.com\/india\/wp-content\/uploads\/2026\/04\/glp.jpeg",1600,1600,false]},"uagb_author_info":{"display_name":"Diksha Kulshreshtha ,M.Sc.,Ph.D. (Molecular Medicine)","author_link":"https:\/\/higoodhealth.com\/india\/author\/diksha01\/"},"uagb_comment_info":0,"uagb_excerpt":"The Drug That Changed Everything \u2014 And Why India Cannot Afford to Ignore It Imagine a once-weekly injection that helps your body release insulin only when blood sugar is high, reduces constant food cravings, and \u2014 in large clinical trials \u2014 lowers the risk of heart attacks by 20% in people who are overweight. This&hellip;","authors":[{"term_id":74,"user_id":28,"is_guest":0,"slug":"diksha01","display_name":"Diksha Kulshreshtha ,M.Sc.,Ph.D. (Molecular Medicine)","avatar_url":"https:\/\/higoodhealth.com\/india\/wp-content\/litespeed\/avatar\/23494c9101089ad44ae88ce9d2f56aac.jpg?ver=1779139082","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":""},{"term_id":67,"user_id":23,"is_guest":0,"slug":"vasundhara","display_name":"Dr. Vasundhara, MDS (Oral &amp; Maxillofacial Surgery), BDS","avatar_url":"https:\/\/higoodhealth.com\/india\/wp-content\/litespeed\/avatar\/23494c9101089ad44ae88ce9d2f56aac.jpg?ver=1779139082","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":""}],"_links":{"self":[{"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/posts\/4192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/comments?post=4192"}],"version-history":[{"count":9,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/posts\/4192\/revisions"}],"predecessor-version":[{"id":4224,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/posts\/4192\/revisions\/4224"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/media\/4198"}],"wp:attachment":[{"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/media?parent=4192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/categories?post=4192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/tags?post=4192"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/higoodhealth.com\/india\/wp-json\/wp\/v2\/ppma_author?post=4192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}